MWNA
AYLA

Marshall Wace North America’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Marshall Wace North America’s Portfolio AYLA Stock Details AYLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$559K Hold
49,266
– – ﹤0.01% 1090
2021
Q2 		$502K Buy
+49,266
New +$506K ﹤0.01% 1175

Other funds holding AYLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace North America's AYLA Position: Q3 2021 in Review

Marshall Wace North America held its Ayala Pharmaceuticals, Inc. Common Stock (AYLA) position steady in Q3 2021 at 49,266 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Marshall Wace North America first reported a position in AYLA in Q2 2021 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold AYLA as of Q3 2021.

  • Marshall Wace North America held 49,266 shares of Ayala Pharmaceuticals, Inc. Common Stock worth $559K as of Q3 2021.
  • Marshall Wace North America left its Ayala Pharmaceuticals, Inc. Common Stock share count unchanged in Q3 2021.
  • Ayala Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1090 holding.
  • Marshall Wace North America first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2021 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.